#USA #San Diego #Robbins LLP #Tenax Therapeutics #Levosimendan

Robbins LLP Informs Investors of Class Action Against Tenax Therapeutics

In recent news, the shareholder rights law firm Robbins LLP has issued a significant alert to investors concerning Tenax Therapeutics, Inc. (NASDAQ: TENX). A class action lawsuit has been filed on behalf of all individuals and entities that purchased or otherwise acquired Tenax shares during an alleged class period from November 13, 2023, to August 7, 2026. This development has caught the attention of investors, particularly those affected by the company’s recent troubles.

Overview of Tenax Therapeutics

Tenax Therapeutics is a company in the pharmaceutical sector that focuses on innovative therapies for conditions affecting the cardiopulmonary system. The firm has primarily concentrated on a treatment known as levosimendan, which it has been developing for heart failure patients, particularly those with preserved ejection fraction (PH-HFpEF).

Allegations Against Tenax Therapeutics

According to the complaint, Tenax has allegedly misrepresented important information regarding levosimendan and its efficacy. Prior to the class period, the company presented results from its Phase 2 HELP trial, which suggested significant improvements in patients’ walking distances. This statement was crucial as it set the expectations for the subsequent Phase 3 LEVEL study, designed to confirm these results in a broader population.

However, during the class period, it is alleged that Tenax failed to disclose key information that could have affected investors' decisions. Specific allegations include:
1. Inaccurate Claims: The effectiveness of levosimendan was overstated, with real data suggesting it might not be as effective as claimed.
2. Misleading Statements: Public communications from Tenax implied a ‘de-risked’ development approach that was not backed by the actual clinical data.
3. Consequences on Stock Price: On August 10, 2026, following the announcement that the LEVEL study did not meet primary and secondary endpoints, Tenax’s stock plummeted by nearly 90%, resulting in heavy losses for investors.

Investor Actions and Timeline

Investors who acquired Tenax securities during the class period and have experienced significant losses are encouraged to contact Robbins LLP for more details regarding the class action. Those interested in participating as a lead plaintiff—an individual representing the entire class during litigation—have until December 28, 2026, to initiate such a process.

Additionally, it is important to note that potential plaintiffs do not need to take on the lead role to benefit from any recovery that may arise from the lawsuit.

Robbins LLP reminds that it represents shareholders on a contingency basis, meaning there are no upfront costs, making the legal process accessible to all affected investors.

Conclusion

As this situation unfolds, it is critical for Tenax Therapeutics investors to stay updated on the developments of the lawsuit. The ramifications of misleading information can be profound, not only affecting individual investments but also market perceptions regarding the integrity of pharmaceutical companies. Investors should consider reaching out to Robbins LLP to assess their eligibility and take the necessary steps to protect their interests during this legal proceeding. For more information, interested parties can submit inquiries via the law firm's website or call their dedicated legal team.

In summary, while the legal landscape can be complex, organizations like Robbins LLP are committed to advocating for shareholders who may have been unjustly harmed by corporate actions. Investors are encouraged to stay informed and proactive as this class action moves forward.